Cutaneous reactions to aspirin and nonsteroidal antiinflammatory drugs

Clinical Reviews in Allergy and Immunology

Volumn 24, Issue 2, 2003, Pages 125-135

  Sánchez Borges, Mario ^a,b   Capriles Hulett, Arnaldo ^a   Caballero Fonseca, Fernan ^a  

^a Centro Medico Docente La Trinidad   (Venezuela)

^b Clinica El Avila   (Venezuela)

Author keywords

Acetylsalycilic acid; Angioedema; Aspirin; COX 2 inhibitors; Cyclooxygenase 2; Non steroidal antiinflammatory drugs (NSAIDs); Urticaria

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CHOLINE MAGNESIUM TRISALICYLATE; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; MECLOFENAMIC ACID; MEFENAMIC ACID; MELOXICAM; NABUMETONE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PARECOXIB; PIROXICAM; PYRAZOLONE DERIVATIVE; ROFECOXIB; SALICYLAMIDE; SALICYLATE SODIUM; SALSALATE; SULINDAC; UNINDEXED DRUG; VALDECOXIB;

ANGIONEUROTIC EDEMA; ARACHIDONIC ACID METABOLISM; ASTHMA; CONJUNCTIVITIS; CONTACT DERMATITIS; CONTROLLED STUDY; CROSS REACTION; DESENSITIZATION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SELECTIVITY; ERYTHEMA MULTIFORME; ERYTHEMA NODOSUM; HUMAN; MAJOR CLINICAL STUDY; PATHOGENESIS; REVIEW; RHINOSINUSITIS; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VASCULITIS;

ANGIONEUROTIC EDEMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CROSS REACTIONS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG ERUPTIONS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PREVALENCE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; URTICARIA;

EID: 0037391148     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1385/CRIAI:24:2:125     Document Type: Review

References (50)

1. Woodbury, D. M. and Fingl, E. Analgesic-antipyretics, antiinflammatory agents and drugs employed in the therapy of gout, in The Pharmacological Basis of Therapeutics. Goodman, L. S. and Gilman, A., eds., Macmillan Publishing Co., Inc., New York, 1975.
2. Sánchez-Borges, M. and Capriles-Hulett, A. (2000), Atopy is a risk factor for non-steroidal antiinflammatory drug sensitivity. Ann. Allergy Asthma Immunol. 84, 101-106.
3. Quiralte, J., Blanco, C., and Castillo, R. (1996), Intolerance to nonsteroidal antiinflammatory drugs: results of controlled challenges in 98 patients. J. Allergy Clin. Immunol. 98, 678-685.
4. Rosario, N. A. and Ribeiro, A. C. (2000), Achados clínicos da sensibilidades a analgésicos e antiinflamatorios não-hormonais. Rev. Assoc. Med. Bras. 46, 201-206.
5. Capriles-Behrens, E., Caplin, J., and Sánchez-Borges, M. (2000), Facial angioedema in a selected pediatric atopic population. J. Inv. Allergol. Clin. Immunol. 10, 277-279.
6. Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., and DuBois, R. N. (1994), Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107, 1183-1188.
7. Lipsky, P. E. (1999), The clinical potential of cyclooxygenase-2-specific inhibitors. Am. J. Med. 106, 51S-57S.
8. Fu, J. Y., Masferrer, J. L., Seibert, M., Raz, A., and Needleman, P. (1990), The induction and suppression of prostaglandin H2 synthase (cyclo-oxygenase) in human monocytes. J. Biol. Chem. 262, 16,737-16,740.
9. Feldman, M. and McMahon, A. T. (2000), Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal antiinflammatory drugs, with less gastrointestinal toxicity? Ann. Intern. Med. 132, 134-143.
10. 2 production in healthy subjects. Thromb. Res. 17, 317-327.
11. Patrignani, P., Panara, M. R., and Greco, A. (1994), Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J. Pharmacol. Exp. Ther. 271, 1705-1712.
12. Fitzgerald, G. A. and Patrono, C. (2001), The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 345, 433-442.
13. Sánchez-Borges, M., Capriles-Hulett, A., and Caballero-Fonseca, F. (2001), NSAID hypersensitivity in the COX-2 inhibitor era. Allergy Clin. Immunol. Intl. 13, 211-218.
14. Szczeklik, A., Gryglewski, R. S., and Czerniawska-Mysik, G. (1977), Clinical patterns of hypersensitivity to nonsteroidal antiinflammatory drugs and their pathogenesis. J. Allergy Clin. Immunol. 60, 276-284.
15. Pérez, C., Sánchez-Borges, M., and Capriles-Hulett, A. (2001), Pretreatment with montelukast blocks NSAID-induced urticaria and angioedema. J. Allergy Clin. Immunol. 108, 1060-1061.
16. Asero, R. (2000), Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria. Ann. Allergy Asthma Immunol. 85, 156-157.
17. Kowalski, M. L., Bienkiewicz, B., and Woszcek, G. (1999), Diagnosis of pyrazolone drug sensitivity: Clinical history versus skin testing and in vitro testing. Allergy Asthma Proc. 20, 347-352.
18. Strom, B. L., Carson, J. L., Lee Morse, M., West, S. L., and Soper, K. A. (1987), The effect of indication on hypersensitivity reactions associated with Zomepirac sodium and other nonsteroidal antiinflammatory drugs. Arthritis Rheum. 30, 1142-1148.
19. Stevenson, D. D. (2000), Approach to the patient with a history of adverse reactions to aspirin or NSAIDs: diagnosis and treatment. Allergy Asthma Proc. 21, 25-31.
20. Vervloet, D., Pradal, M., and Castelain, M. Drug Allergy. Pharmacia & Upjohn, Uppsala, Sweden, 1999.
21. Stevenson, D. D., Sánchez-Borges, M., and Szczeklik, A. (2001), Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes (editorial). Ann. Allergy Asthma Immunol. 87, 1-4.
22. Sánchez-Borges, M., Capriles-Hulett, A., Fernández-Caldas, E., Suárez-Chacón, R., Caballero, F., Castillo, S., et al. (1997), Mite-contaminated foods as a cause of anaphylaxis. J. Allergy Clin. Immunol. 99, 738-743.
23. Blanco, C., Quiralte, J., Castillo, R., Delgado, J., Arteaga, C., Barber, D., et al. (1997), Anaphylaxis after ingestion of wheat flour contaminated with mites. J. Allergy Clin. Immunol. 99, 308-313.
24. Sánchez-Borges, M., Capriles-Hulett, A., Capriles-Behrens, E., and Fernández-Caldas, E. (1997), A new triad: densitivity to aspirin, allergic rhinitis, and severe allergic reaction to ingested aeroallergens. Cutis 59, 311-314.
25. Sánchez-Borges, M., Capriles-Hulett, A., Suárez-Chacón, R., and Fernández-Caldas, E. (2001), Oral anaphylaxis from mite ingestion. Allergy Clin. Immunol. Intl. 13, 33-35.
26. Andri, L., Senna, G., and Betteli, C. (1994), Tolerability of nimesulide in aspirin-sensitive patients. Ann. Allergy 72, 29-32.
27. Bavbek, S., Celik, G., and Ediger, D. (1999), The use of nimesulide in patients with acetylsalicylic acid and nonsteroidal antiinflammatory drug intolerance. J. Asthma 36, 657-663.
28. Kosnik, M., Music, E., and Mattaz, F. (1998), Relative safety of meloxicam in NSAID-intolerant patients. Allergy 53, 1231-1233.
29. Nettis, E., Di Paola, R., and Ferrarini, A. (2001), Meloxicam in hypersensitivity to NSAIDs. Allergy 56, 803-804.
30. Sánchez-Borges, M., Capriles-Hulett, A., and Caballero-Fonseca, F. (2001), Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann. Allergy Asthma Immunol. 87, 201-204.
31. Canadian ADR Newsletter 10, 1-5, 2000.
32. Adverse Drug Reactions Advisory Committee (ADRAC). (2000), Australian Adverse Drug Reactions Bulletin 19, 6-7.
33. Knowles, S., Shapiro, L., and Shear, N. H. (2001), Should Celecoxib be contraindicated in patients who are allergic to sulphonamides? Drug Saf. 24, 239-247.
34. Wiholm, B. (2001), Identification of sulphonamide-like adverse drug reactions to Celecoxib in the World Health Organization Database. Current Med. Res. Opinion 17, 210-216.
35. Warner, T. D., Giuliano, F., Voinovic, I., Bukasa, A., Mitchell, J. A., and Vane, J. R. (1999), Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl. Acad. Sci. USA 96, 7563-7568.
36. Berges-Gimeno, M. P., Camacho-Garrido, E., and Garcia-Rodriguez, R. M. (2001), Rofecoxib, a selective high affinity COX-2 inhibitor has proved to be safe in urticaria/angioedema associated with NSAID intolerance. Allergy 56, 49.
37. Pacor, M. L., Di Lorenzo, G., and Brasi, D. (2001), COX-2 inhibitors in patients with adverse reaction to nonsteroidal anti-inflammatory drugs. Allergy 56, 49.
38. Valero, A. L., Baltasar, M. A., and Pau, E. L. (2001), Rofecoxib a COX-1 sparing in NSAID sensitive patients. Allergy 56, 221.
39. Boechncke, W. H., Kauffman, R., and Zollner, T. M. (2001), Tolerance to the selective cyclooxygenase-2 inhibitor Rofecoxib in patients intolerant to nonsteroidal antiphlogistics. Allergy 56, 222.
40. Matucci, A., Rossi, D., and Cecchi, L. (2001), Rofecoxib a new alternative in patients with intolerance to NSAIDs. Allergy 56, 222.
41. Szczeklik, A., Nizankowska, E., and Bochenek, G. (2000), Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin. Exp. Allergy 31, 219-225.
42. Dahlen, B., Szczeklik, A., and Murray, J. J. U. (2001), Celecoxib in patients with asthma and aspirin intolerance. N. Engl. J. Med. 344, 142.
43. Yoshida, S., Ishizaki, K., and Onuma, K. (2000), Selective cyclooxygenase 2 inhibitor in patients with aspirin-induced asthma. J. Allergy Clin. Immunol. 106, 1201-1202.
44. Stevenson, D. D. and Simon, R. A. (2001), Lack of cross-reactivity between Rofecoxib and aspirin in aspirin-sensitive asthmatic patients with asthma. J. Allergy Clin. Immunol. 108, 47-51.
45. Pang Leong, K., Ying Tang, Ch., Thong, B., and Hee Chang, H. (2002), The safety of rofecoxib in patients with NSAID-induced urticaria and angioedema. J. Allergy Clin. Immunol. 109, S140.
46. Fernández-Melendez, S., Miranda, A., Carmona, M. J., Diaz, J., Barceló, J. M., Vega, J. M., et al. (2002), Tolerance of rofecoxib in patients with adverse reactions to nonsteroidal antiinflammatory drugs (NSAIDs). J. Allergy Clin. Immunol. 109, S140.
47. Dama, A. R., Liccardi, G., Lobefalo, G., Bonadonna, P., Schiappoli, M., Crivellaro, M., et al. (2002), Celecoxib, a new selective COX-2 inhibitor, is a safe alternative drug in highly NSAID-intolerant patients. J. Allergy Clin. Immunol. 109, S141.
48. Settipane, G. A. (1983), Aspirin and allergic diseases. Am. J. Med. 74, 102-110.
49. Strom, B. L., Carson, J. L., and Schinnar, R. (1988), The effect of indication on the risk of hypersensitivity reactions associated with tolmetin sodium versus other nonsteroidal antiinflammatory drugs. J. Rheumatol. 15, 695-699.
50. Stevenson, D. D. and Simon, R. A. Sensitivity to aspirin and non steroidal antiinflammatory drugs, in Allergy, Middleton, E. R. and Reed, C. E., ed. C. V. Mosby, St. Louis, 1992, pp. 1747-1765.